The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant efficacy in clinical trials for managing obesity. Unlike some existing weight loss treatments, retatrutide appears to offer a more substantial decrease in body size and benefit metabolic function, partic